Novel Drug Treatments of Progressive Radioiodine-Refractory Differentiated Thyroid Cancer
- 11 December 2018
- journal article
- research article
- Published by Elsevier BV in Endocrinology and Metabolism Clinics of North America
- Vol. 48 (1), 253-268
- https://doi.org/10.1016/j.ecl.2018.10.009
Abstract
No abstract availableKeywords
This publication has 67 references indexed in Scilit:
- Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trialThe Lancet Oncology, 2012
- Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular ElementsClinical Cancer Research, 2012
- Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activationJCI Insight, 2011
- Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging CorrelationClinical Cancer Research, 2010
- Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium studyThe Lancet Oncology, 2010
- Phase II Trial of Sorafenib in Metastatic Thyroid CancerJournal of Clinical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- Phase II Trial of Sorafenib in Advanced Thyroid CancerJournal of Clinical Oncology, 2008
- BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma CellsMolecular Cancer Research, 2008
- Vascular Endothelial Growth Factor in Thyroid CancersCancer Biotherapy & Radiopharmaceuticals, 2005